Introduction {#sec1-1}
============

Irritable bowel syndrome (IBS) is a common functional gastrointestinal (GI) disorder with a worldwide prevalence of 9-25% \[[@ref1],[@ref2]\]. It affects mainly young patients (below the age of 50 years) and is one of the most common reasons for patients to be seen in outpatient gastroenterology clinics \[[@ref3]-[@ref5]\]. In addition to decreased quality of life due to GI and extraintestinal manifestations, IBS has also been associated with a considerable healthcare cost burden and work-school absenteeism \[[@ref2],[@ref6]-[@ref9]\] The Rome criteria, the gold standard for diagnosing IBS, take into account the duration of GI symptoms and other factors such the association of symptoms with bowel movement and stool caliber or frequency \[[@ref1],[@ref3]\].

Asthma, another condition known to reduce patients' quality of life, is commonly associated with GI conditions such as gastroesophageal reflux disease and eosinophilic esophagitis \[[@ref10],[@ref11]\]. The incidence of asthma with coexisting GI comorbidities has been rising worldwide \[[@ref1]\]. The association between IBS and asthma was first identified in the 1990s; however, the question of how the 2 conditions are related is still unclear \[[@ref1],[@ref12]\]. Patients with IBS and coexisting atopic disease have been shown to have higher immunoglobulin E levels and more likelihood of self-reported food intolerance. However, there have also been contradictory studies that showed no association between IBS and pulmonary conditions such as chronic bronchitis \[[@ref5],[@ref13],[@ref14]\]. This systematic review and meta-analysis summarizes the available literature pertaining to the association of IBS and asthma in the adult population.

Materials and methods {#sec1-2}
=====================

A comprehensive literature review was completed using the MEDLINE and EMBASE databases through January 2019. All research studies that evaluated IBS and asthma in adults were reviewed. Published case-control, cross-sectional and cohort studies that evaluated the association between IBS and asthma were included. Pediatric and animal studies, editorials, letters and studies that did not provide information on the number of IBS or asthma patients were excluded. Based on the inclusion and exclusion criteria, a total of 10 studies were selected and analyzed for the meta-analysis.

The systematic review was conducted independently by 2 investigators (FD, EM), who independently screened the study titles and abstracts based on the inclusion and exclusion criteria. Key search terms included "irritable bowel syndrome", "functional bowel disorder", and "asthma". A more detailed list of search terms has been provided in the supplementary data. The study was conducted in accordance with the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) statement and study quality was assessed using the Newcastle-Ottawa scale (NOS).

Statistical analysis {#sec2-1}
--------------------

Statistical analysis was performed using STATA Version 15 for Windows (StataCorp., Lake Station, TX, USA). A random effects meta-analysis was conducted, and heterogeneity was assessed using I-squared statistics to measure the variability across the studies included in the meta-analysis. The results were presented as odds ratios (OR) and a sensitivity analysis was conducted that included only the case control studies. A separate meta-analysis included studies that explored the risk of IBS in asthmatic patients and *vice versa*. Publication bias was assessed by funnel plot and the Harbord test for small-study effects.

Results {#sec1-3}
=======

A total of 634 studies (186 from MEDLINE and 448 from EMBASE) were obtained using relevant search terms. One hundred fifty-three duplicate studies were removed. Manual review of the remaining 481 study titles and abstracts yielded 23 pediatric studies, 8 case reports, 1 duplicate study, and 431 irrelevant studies, which were excluded. Of the remaining 18 studies, 7 studies lacked the required data and 1 study was found to have children in the cohort. The remaining 10 eligible studies (8 case-control and 2 cross-sectional), with a total of 155,032 subjects, were included in the analysis ([Fig. 1](#F1){ref-type="fig"}). Basic characteristics of the 10 studies are described in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}.

###### 

Baseline characteristics of studies that identified asthmatics and looked for the presence of IBS
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###### 

Baseline characteristics of studies that identified patients with IBS and looked for the presence of asthma
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Studies were divided into 2 groups: the first group included studies that identified asthmatics and looked for the presence of IBS; the second included studies that identified IBS patients and looked for the presence of asthma. Shen *et al* conducted a bidirectional study, therefore included in both groups \[[@ref15]\]. The first group included 7 studies (5 case-controls and 2 cohort studies) with a total of 30,569 asthmatics and 11,9484 controls. The pooled OR was 2.0 (95% confidence interval \[CI\] 1.5-2.8) with an *I*^2^ value of 69.5% (P=0.03) ([Table 3](#T3){ref-type="table"}, [Fig. 2](#F2){ref-type="fig"}). A sensitivity analysis including only the 5 case-control studies for the meta-analysis showed an *I*^2^ value of 0% (P=0.8) and an OR of 2.6 (95%CI 1.9-3.5) ([Table 4](#T4){ref-type="table"}, [Fig. 3](#F3){ref-type="fig"}). The second group included 4 studies with 30,415 IBS patients and 12,4107 non-IBS patients. The pooled OR was 2.2 (95%CI 1.3-3.9) with *I*^2^ 81.3% (P=0.001) ([Table 5](#T5){ref-type="table"}, [Fig. 4](#F4){ref-type="fig"}). A funnel plot was then constructed separately, including the respective studies for the outcome of IBS and asthma. For the meta-analysis that included 7 studies of the outcome of IBS, the coefficient of bias using the Harbord test was -0.2 (P=0.78), indicating the absence of small-study effects ([Fig. 5](#F5){ref-type="fig"}).

###### 

Case-control and cross-sectional studies looking at the presence/outcome of irritable bowel syndrome in asthmatics
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###### 

Case-control studies looking for the presence of irritable bowel syndrome in asthmatics
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###### 

Studies looking for the presence of asthma in patients with irritable bowel syndrome
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Discussion {#sec1-4}
==========

IBS manifests with many debilitating symptoms, including abdominal pain, bloating, muscle pain and headache, and diagnosing it can be very challenging, considering the variability and fluctuation of disease symptoms over time and the overlap of symptoms with other conditions, such as lactose intolerance \[[@ref2]-[@ref4],[@ref15]\]. IBS was for a long time described by symptoms of "alternating constipation and diarrhea", but the Rome criteria introduced in the 1980s represented an attempt to better diagnose the condition. The criteria have been revised and improved over time to better classify IBS. The Rome II criteria diagnosed IBS on the basis of the presence of symptoms for at least 12 weeks; however, it did not provide any information about the subtypes of IBS \[[@ref4]\]. The Rome III criteria subclassified IBS into primarily constipation, diarrhea, mixed, or unclassified, based on the stool consistency (using the Bristol stool form scale) \[[@ref4]\]. Further revision led to the Rome IV criteria, according to which symptoms should be present during the last 3 months and for at least 6 months before the diagnosis of IBS \[[@ref4]\].

IBS is also frequently associated with other complicated rheumatologic conditions, such as fibromyalgia and chronic pain disorders \[[@ref8]\]. A prospective study conducted in Taiwan identified 33,729 patients (mean age 51 years) with fibromyalgia and 134,915 patients (mean age 51.5 years) without fibromyalgia using the national health insurance database. The study reported a 1.91 to 3.19-fold greater incidence of IBS in patients with fibromyalgia \[[@ref16]\]. Researchers have recently been turning their attention towards understanding the association of IBS with respiratory pathologies. A recent case-control study with 197 patients (100 with sleep apnea and 97 without sleep apnea) conducted at a sleep laboratory in Iran looked at the association of IBS and sleep apnea. The average age of participants was 42.24±12.05 years (55.4% male). Of the patients who had a positive sleep apnea test, 27.1% also met the IBS diagnostic criteria, compared to 8.2% of those who had a negative sleep apnea test. This study showed a higher prevalence of IBS in patients with sleep apnea, irrespective of its severity \[[@ref17]\]. A case-control study conducted in Egypt recruited 133 medical students, 50 with IBS (44 female) and 83 healthy controls (50 female), and showed that IBS patients are at a significantly higher risk of developing chronic rhinosinusitis than non-IBS patients \[[@ref18]\].

In our study, the analysis of most studies from across the world showed a strong association between IBS and asthma. Some studies have also shown that IBS is more prevalent in asthma patients with comorbidities compared to non-asthmatics \[[@ref15]\]. Mast cells release histamine, proinflammatory cytokines and other mediators known to cause hyperresponsiveness in atopic diseases such as asthma. They have also been shown to affect enteric nerve and smooth muscle function \[[@ref19]\]. Omalizumab, a monoclonal antibody used for the management of asthma, also improves allergic GI symptoms \[[@ref20]\]. Interestingly, another mechanism proposed for the association of asthma and GI symptoms is the increase in intestinal permeability, or "leaky gut syndrome" \[[@ref21],[@ref22]\]. Hijazi *et al* reported that children with asthma have increased intestinal permeability compared to non-asthmatics \[[@ref21]\]. A study in France analyzed intestinal permeability in 37 asthmatic adults (mean age 44±16 years) and compared it to results obtained from 13 non-asthmatics with chronic obstructive pulmonary disease (COPD; mean age: 59±1.6 years) and 26 healthy controls (mean age: 43±2 years) \[[@ref23]\]. Measurement of urinary chromium 51-labeled ethylenediaminetetraacetic acid (CrEDTA) was used to study intestinal permeability. The study reports that asthmatics had a significantly higher urinary CrEDTA (2.5±1.95%) compared to the COPD and control groups (1.16±0.48%; P=0.01 and 1.36±0.14%; P=0.006, respectively) \[[@ref23]\]. Although atopy and immune system activation to some extent has been shown to be the pathophysiological mechanism for the association of asthma with functional GI disorders, the overall pathophysiological mechanism is unknown, thus adding another level of complexity to the management of the disorder \[[@ref15],[@ref24]\]. This study has some limitations that should be noted. Some of the potential studies could not be included in the analysis as they were not published studies or were case reports. Secondly, the majority of the studies did not discuss sub-classifications of IBS or the severity of asthma, and although most studies reported that spirometry was performed to confirm the diagnosis of asthma, the results were not discussed in detail. Lastly, the lack of heterogeneity, with statistically significant *I*^2^ of 69.5% and 81.3% for the 2 groups of meta-analysis, is another limitation of this study.

In conclusion, there has been limited research into the association of IBS with asthma \[[@ref25]\]. This analysis looked closely at the current evidence and noted that there is strong association between the 2 conditions. Physicians should keep a high index of suspicion for asthma in patients who present with pulmonary symptoms along with GI symptoms such as abdominal pain or discomfort, change in bowel habits and bloating \[[@ref25]\]. On the same note, IBS patients should be informed about the possible risk of developing asthma or pulmonary symptoms. Some of the interventions that may be included in the management of these patients may include evaluation with spirometry, skin testing with food antigens, or dietary consultation.

###### Summary Box

**What is already known:**

Irritable bowel syndrome (IBS) is very common in patients of all agesBoth IBS and asthma affect quality of life and have a significant healthcare cost burden

**What the new finding is:**

The risk of asthma in patients with IBS is twice the risk in non-IBS patients
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